Radek Spisek, Sotio CEO (Cellestia)

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

In the rather in­su­lar world of biotech, most in­no­va­tion in­evitably comes from a clus­ter of R&D hubs — Cam­bridge, San Fran­cis­co, etc. But some­times suc­cess sto­ries sprout from rocky soil, which is most cer­tain­ly the case with Prague-based So­tio Biotech and its sud­den­ly jam-packed pipeline of can­cer drugs.

Af­ter years in qui­et de­vel­op­ment, So­tio now has $315 mil­lion in new funds to play with from par­ent com­pa­ny PPF Group, an in­vest­ment group found­ed in the Czech Re­pub­lic, as the biotech looks to ad­vance its grow­ing pipeline through ear­ly- and mid-stage tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.